The long-term effect of prednisone in Crohn's disease has been examined in a doubleblind controlled trial. Clinical relapse, recurrence, and extension of the disease were examined in 64 patients followed-up for up to three years. Fourteen patients were withdrawn because of severe symptoms (eight on prednisone and six controls); the withdrawal rate in both groups was 30 % at three years. Nine other patients had radiological recurrence or extension of disease (five prednisone and four controls). Prednisone did not improve the relapse rate, nor did it affect recurrence or extension of disease.
One of the most daunting aspects of Crohn's disease is recurrence after surgery and extension of disease in spite of medical treatment. Short-term steroids lead to remission of symptoms in most patients with Crohn's disease; in one restrospective study (Jones and Lennard-Jones, 1966) 22 of 30 patients responded very quickly to therapy and in the current National Co-operative Crohn' s Disease Study (NCCDS) steroids in a moderate dose (up to 0 75 mg prednisone per kg per day) caused a highly significant reduction in symptoms within two weeks and the improvement was maintained over four months (Singleton, 1976) . Some patients appear to require steroids to control symptoms or 'disease activity' in the long-term and in two recent clinical trials (Willoughby et al., 1971; Rosenberg et al., 1975) where azathioprine was examined, withdrawal of steroids from these patients led to a recurrence of symptoms.
Although steroids reduced the severity of symptoms in acute disease, and in some patients control symptoms in the long term, their value in prevention of recurrence or extension of disease has not been examined. We have conducted a controlled trial to examine the effect of long-term treatment with prednisone on these aspects of Crohn's disease.
Methods

DESIGN OF TRIAL
Patients from South Glamorgan and adjacent areas 'Present address: University Department of Surgery, Leeds General Infirmary, Leeds. Received for publication January 1978 were referred and examined in the clinic which was specially organised for the trial; all patients gave informed consent before entering the study. They were divided into three subgroups: (1) group I had bowel resected for Crohn's disease and had no obvious residual disease; (2) group II had also had recent surgery but there was residual disease; (3) group III were known to have active Crohn's disease but had not had surgery during the previous 12 months.
The patients who entered the trial were free from symptoms and there was no clinical indication for steroid treatment; all of them had contrast radiology to define the site and extent of disease. Those in groups I and II entered the trial within three months of surgery with a few exceptions who were all admitted within one year. The diagnosis was based on the pathology of resected specimens or on radiological findings in some patients entering group III.
Patients excluded Patients were excluded from the trial if they were more than 60 years of age or had evidence of liver disease. Others were excluded if they had active peptic ulceration, severe hypertension, diabetes, previous pulmonary tuberculosis, or if they were pregnant at the onset of the trial.
Trial design and treatment After admission to the trial patients were randomly allocated into groups on active or identical placebo tablets. Neither the patients nor medical staff were aware of the group to which the patients had been Radiological assessment Thirty-five patients who remained in the trial had further gastrointestinal radiology to define the extent of disease. These examinations were repeated after two years in the trial in 22 of the patients, but in nine of the patients after three years, and in four patients after one year in the trial. All of the radiology was carried out by the same two observers (KTE and BWL).
Results
Sixty-four patients were admitted to the trial but five of these were excluded within a few months of admission for reasons unrelated to their Crohn's disease. Two developed symptoms from peptic ulcer and three proved unreliable. The subsequent analysis relates to results from the remaining 59 patients.
Details of numbers in each subgroup and the randomisation are in Table 1 . Twenty-six were admitted to group I, 11 to group II, and 22 to group III. Details of the sex, age, distribution, and duration of disease in the prednisone and control groups are in Table 2 ; details of the patients in the two treatment groups were similar.
Of the 59 patients who completed the first sixmonth period, 54 completed 18 months, and 30 patients remained in the trial for three years. During this three-year period, 14 patients were withdrawn from the trial; eight were in the prednisone and six in the control group (Table 1) . Only two of the 26 patients in group I were withdrawn compared with seven of 11 patients in group II and five of 22 patients in group III. (14) 33 (8) 26 (6) The randomisation of patients on to treatment with either prednisone or placebo is given for the three subgroups; the numbers do not include five patients who were withdrawn during the first treatment period for reasons other than Crohn's disease. The number of patients withdrawn from each subgroup is given in parentheses. The percentages of patients withdrawn from and remaining in the trial are represented as a 'life table estimate' in the Figure, which shows a withdrawal rate of 30 % at three years in both treatment groups; there was no significant difference in the experience of the two groups during the three-year period as judged by the log rank test (Peto et al., 1976 (Peto et al., , 1977 .
The site of the original disease in patients withdrawn from the trial was the small bowel in six, small bowel and colon in seven, and colon alone in one patient. Four of these patients subsequently had medical therapy which included an increased dose of steroids for several months. The remaining 10 patients had further surgery which included resection of the ileum in six patients combined with a right hemicolectomy in five of them. One patient had an abdominoperineal resection, one had a perineal U607 The number of patients who were withdrawn from the trial or had a single medical relapse are shown together with those in whom there was radiological evidence of either recurrence or extension of disease. The figures are given for the prednisone and control patients in each group. present on the second examination; minor differences between the examination were not included in the results.
Figures for recurrence rates have varied from different centres; they are affected by the definition of recurrence, differences between patient groups and with the site of disease. Most figures are high and the longer the period for which a group is followed-up the higher the rate becomes. Crohn and Yarnis (1958) followed-up 542 cases for up to 25 years and only 51 of these remained well. Cooke (1955) reported a figure of 45 % at two years, 68 % at five years, and 78% at 10 years in a group of patients receiving both medical and surgical treatment. Lennard-Jones and Stalder (1967) used actuarial methods to calculate that one-third of all patients had symptomatic relapse within five years of a surgical resection of the terminal ileum and 50% after 10 years. Another surgical series from the Mayo Clinic (Van Patter, 1954) showed a recurrence of disease in 80 % of 270 patients, 15 years after the initial operation. Another large study involving 168 patients from Leeds (de Dombal et al., 1971) showed an overall recurrence rate of 34% in patients seen between 1939 and 1968. The recurrence rate was less in patients with involvement mainly of the large rather than small bowel and was affected by age, with high recurrence rates in children and adolescents and low rates over the age of 60 years. Our results are compatible with some of the values in previous studies; the considerable variation from one centre to another emphasises the essential part of a control group in any study where the effect of therapeutic measures are examined in the long term.
A retrospective study by Cooke and Fielding (1970) suggested that long-term steroids were detrimental ; they examined the clinical course of 300 patients, 124 of whom had been given steroids, and found that the annual risk of surgery was 20% in those given steroids compared with only 10% without steroids. The authors pointed out that some of the severe complications and increased mortality were directly due to steroids. The current NCCD study in the United States (Summers and Singleton, 1977) again showed no benefit from steroids in the long term. The prophylactic effect of a low dose (less than 20 mg daily) was examined after one and two years and compared with control patients; clinical or radiological deterioration had occurred in 32 % in one year and in 69 % after two years with no significant difference between the groups.
There are many difficulties involved in an assessment of long-term treatment in Crohn's disease. It is difficult to obtain a large homogeneous group of patients in a single centre and then follow them up for a sufficiently long time. Because of these problems, two recent studies (Multicentre Trial, 1977; Singleton, 1976; Summers and Singleton, 1977) have included many centres. It is particularly difficult to follow a group of patients for a long time and to maintain uniform standards for assessment and relapse. The study on sulphasalazine (Multicentre Trial, 1977) showed no trend in favour of the drug over the control group but the authors were concerned about difficulties in the trial due to small numbers, the involvement of nine hospitals, as well as the varied nature of the disease. The NCCDS group introduced a score of disease activity (Best et al., 1976) to overcome some of the difficulties in grading clinical severity. Some of these assessments are subjective and have been open to criticism on this basis. We tried to overcome some of the difficulties by creating three subgroups of patients, the first two of which were fairly homogeneous. The results are largely based on recurrence of disease in 14 patients who had to be withdrawn from the trial, and another nine patients who had evidence of radiological recurrence or disease extension.
We conclude that small doses of prednisone appear to have no beneficial effect on recurrence or clinical relapse in Crohn's disease but would recognise that there are patients who benefit symptomatically from this drug in both the short and long term. 
